Project Grant R01CA290791
Award Date
6/11/25
Completion Date
5/31/30
Dollars Obligated
$701K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $532,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Icahn School of Medicine at Mount Sinai. The grant, effective April 1, 2025 through March 31, 2030, will fund research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The project aims to study the transcriptional programs and secreted...
The National Cancer Institute (NCI) awarded a $100,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization located in New York, NY. The grant, running from January 1, 2025 to December 31, 2028, will fund research to develop a nanoparticle-based RNA interference (RNAi) therapy targeting the tumor immune microenvironment in multiple myeloma (MM). The project aims to...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Icahn School of Medicine at Mount Sinai for $701,538 on December 4, 2024. The grant will fund research to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC). Key objectives include determining how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance of SCLC...
This $674,440 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The grant supports research at the University of Miami to comprehensively define the clinical impact of myeloma-defining genomic and immune events among myeloma precursor conditions (MPCs), in order to differentiate benign from malignant MPCs. The study will utilize novel single-cell whole genome sequencing (scWGS) to characterize the subclonal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $499,902 to Rowan University to develop a novel MCL-1 inhibitor, KS18, and investigate its potential to reverse chemotherapeutic resistance in multiple myeloma (MM). The key objectives are to: 1) determine if MCL-1 inhibition via KS18 can reverse acquired resistance to standard MM treatments like bortezomib in vitro, 2) evaluate if KS18 can overcome bortezomib resistance in MM...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai aims to develop a novel single-cell multi-omic profiling method called SHARE-ME-SEQ. This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level to provide unprecedented insights into the regulatory mechanisms underlying cancer cell plasticity and metastasis, with a focus on acute myeloid...
The federal Project Grant award in the amount of $2,028,000.00 was provided by the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) federal grant program, to the Icahn School of Medicine at Mount Sinai. The grant, awarded on April 1, 2025, supports advanced biomedical research focused on identifying "epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer." The Icahn School of Medicine at Mount Sinai, a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying inhibitors of the chromatin reader SGF29 as a potential novel therapeutic approach for acute myeloid leukemia (AML). The project will implement high-throughput screening assays developed by the researchers to screen chemical compound libraries and identify selective SGF29...
The Department of the Army Medical Command awarded a $839,694 Project Grant to the Icahn School of Medicine at Mount Sinai to support research titled "Dissecting the Regulation of C-Myc by HDAC6 and Its Role in the Anticancer Activity of HDAC6." The grant period runs from September 30, 2022 through September 29, 2025. The research will investigate the role of histone deacetylase 6 (HDAC6) in regulating the oncogene C-Myc and HDAC6's potential anticancer effects. This work aligns with...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is providing $1,014,000.00 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The research, which is scheduled to take place from September 1, 2024 to August 31, 2028, will leverage the institution's expertise in areas such as cancer biology, immunology, and clinical...